Arrowhead Pharmaceuticals (ARWR) Cash from Operations (2010 - 2026)
Arrowhead Pharmaceuticals (ARWR) posted Cash from Operations of 84442000.0 for Q1 2026, up 526.38% on a QoQ basis from 13481000.0 in Q4 2025, and down 81.65% year-over-year from 460053000.0 in Q1 2025.
Arrowhead Pharmaceuticals (ARWR) Cash from Operations (2010 - 2026) Analysis & Trends
Arrowhead Pharmaceuticals' Cash from Operations history runs 17 years deep, the most recent figure standing at 84442000.0 for Q1 2026.
- Quarterly Cash from Operations fell 81.65% year-over-year to 84442000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 36306000.0 (down 159.37% YoY) and the FY2025 annual result came in at 179552000.0, up 138.79% from the prior year.
- Cash from Operations was 84442000.0 for Q1 2026 at Arrowhead Pharmaceuticals, up from 13481000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 460053000.0 in Q1 2025 and bottomed at 154720000.0 in Q2 2025.
- A 5-year average of 24358176.47 and a median of 68737000.0 in 2022 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2024 — Cash from Operations sank 455.51% — and 2025, when it jumped 598.02%.
- Arrowhead Pharmaceuticals' Cash from Operations stood at 75516000.0 in 2022, then slumped by 56.05% to 117840000.0 in 2023, then fell by 24.13% to 146272000.0 in 2024, then soared by 109.22% to 13481000.0 in 2025, then soared by 526.38% to 84442000.0 in 2026.
- Business Quant data shows ARWR's Cash from Operations at 84442000.0 in Q1 2026, 13481000.0 in Q4 2025, and 20491000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 201.34 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.17 Mn |
| 10 | Arrowhead Pharmaceuticals | 11.98 Bn | 10.18 Bn | - | 84.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 84.44 Mn |
| Mar 31, 2026 | 84.44 Mn |
| Dec 31, 2025 | 13.48 Mn |
| Dec 31, 2025 | 13.48 Mn |
| Sep 30, 2025 | 20.49 Mn |
| Sep 30, 2025 | 20.49 Mn |
| Jun 30, 2025 | -154.72 Mn |
| Jun 30, 2025 | -154.72 Mn |
| Mar 31, 2025 | 460.05 Mn |
| Mar 31, 2025 | 460.05 Mn |
| Dec 31, 2024 | -146.27 Mn |
| Dec 31, 2024 | -146.27 Mn |
| Sep 30, 2024 | -137.22 Mn |
| Sep 30, 2024 | -137.22 Mn |
| Jun 30, 2024 | -115.42 Mn |
| Jun 30, 2024 | -115.42 Mn |
| Mar 31, 2024 | -92.38 Mn |
| Mar 31, 2024 | -92.38 Mn |
| Dec 31, 2023 | -117.84 Mn |
| Dec 31, 2023 | -117.84 Mn |